Physician profile
Stephan U Schuele
NPI 1427047000
$226,863.32
in general payments reported to CMS, 2019-2025
12 companies · $43K in 2025
The $43K reported for 2025 was more than what 97% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $31K · 2021: $21K · 2022: $17K · 2023: $42K · 2024: $36K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $81K · Travel and Lodging: $15K · Honoraria: $13K · Consulting Fee: $9,503 · Food and Beverage: $2,999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $80,551.00 |
| Travel and Lodging | $15,367.90 |
| Honoraria | $13,037.50 |
| Consulting Fee | $9,503.00 |
| Food and Beverage | $2,999.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $64,510.45 | 2022-2025 | |
| Neurelis, INC. | $50,817.38 | 2020-2025 | Valtoco |
| Sk Life Science, INC. | $50,186.35 | 2020-2025 | Xcopri |
| Greenwich Biosciences, INC. | $26,779.26 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $12,215.61 | 2019-2020 | |
| Eisai INC. | $9,876.00 | 2019-2020 | |
| Ucb, INC. | $7,707.95 | 2024-2025 | Fintepla |
| Monteris Medical Corporation | $4,200.00 | 2020-2021 | |
| Livanova USA, INC. | $400.00 | 2021 | |
| Cadwell Industries, INC | $156.00 | 2023 | |
| Supernus Pharmaceuticals, INC. | $14.32 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephan Schuele listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.